A team of researchers from the US, Europe, Taiwan and Japan has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials.
A team of researchers from the US, Europe, Taiwan and Japan has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials.